Company Analysis Gland Pharma Limited
1. Summary
Advantages
- The stock's return over the last year (4.51%) is higher than the sector average (-41.78%).
- The company's current efficiency (ROE=8.85%) is higher than the sector average (ROE=7.22%)
Disadvantages
- Price (1810.05 βΉ) is higher than fair price (511.08 βΉ)
- Dividends (1.07%) are below the sector average (9.59%).
- Current debt level 3.17% has increased over 5 years from 0.2047%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Gland Pharma Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.6% | 4.7% | -1.6% |
| 90 days | -16% | 12.8% | -3.3% |
| 1 year | 4.5% | -41.8% | 12.2% |
GLAND vs Sector: Gland Pharma Limited has outperformed the "Healthcare" sector by 46.28% over the past year.
GLAND vs Market: Gland Pharma Limited has significantly underperformed the market by -7.66% over the past year.
Stable price: GLAND is not significantly more volatile than the rest of the market on "National Stock Exchange Of India" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GLAND with weekly volatility of 0.0867% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1810.05 βΉ) is higher than the fair price (511.08 βΉ).
Price is higher than fair: The current price (1810.05 βΉ) is 71.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (38.2) is lower than that of the sector as a whole (59.31).
P/E vs Market: The company's P/E (38.2) is lower than that of the market as a whole (53.81).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.38) is lower than that of the sector as a whole (6.53).
P/BV vs Market: The company's P/BV (3.38) is lower than that of the market as a whole (5.55).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.21) is lower than that of the sector as a whole (8.62).
P/S vs Market: The company's P/S indicator (5.21) is lower than that of the market as a whole (16.9).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (21.03) is lower than that of the sector as a whole (141.72).
EV/Ebitda vs Market: The company's EV/Ebitda (21.03) is lower than that of the market as a whole (36.92).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 14.19% over the last 5 years.
Earnings Slowdown: The last year's return (-1.1%) is below the 5-year average return (14.19%).
Profitability vs Sector: The return for the last year (-1.1%) is lower than the return for the sector (38.16%).
5.4. ROE
ROE vs Sector: The company's ROE (8.85%) is higher than that of the sector as a whole (7.22%).
ROE vs Market: The company's ROE (8.85%) is lower than that of the market as a whole (12.05%).
5.5. ROA
ROA vs Sector: The company's ROA (7.25%) is higher than that of the sector as a whole (6.7%).
ROA vs Market: The company's ROA (7.25%) is lower than that of the market as a whole (7.41%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.91%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (15.54%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.07% is below the average for the sector '9.59%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 1.07% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 1.07% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
